WO2008030964A2 - Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits - Google Patents
Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits Download PDFInfo
- Publication number
- WO2008030964A2 WO2008030964A2 PCT/US2007/077763 US2007077763W WO2008030964A2 WO 2008030964 A2 WO2008030964 A2 WO 2008030964A2 US 2007077763 W US2007077763 W US 2007077763W WO 2008030964 A2 WO2008030964 A2 WO 2008030964A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- zeolite
- calcium
- noncalcium
- zeolites
- Prior art date
Links
- 239000010457 zeolite Substances 0.000 title claims abstract description 85
- 159000000007 calcium salts Chemical class 0.000 title claims description 10
- 230000002439 hemostatic effect Effects 0.000 title description 7
- 229910021536 Zeolite Inorganic materials 0.000 claims abstract description 55
- 239000008280 blood Substances 0.000 claims abstract description 54
- 210000004369 blood Anatomy 0.000 claims abstract description 54
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims abstract description 54
- -1 Ca2+ ions Chemical class 0.000 claims abstract description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 17
- 239000001110 calcium chloride Substances 0.000 claims description 17
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 230000023555 blood coagulation Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 229910001622 calcium bromide Inorganic materials 0.000 claims description 2
- 229940059251 calcium bromide Drugs 0.000 claims description 2
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 claims description 2
- 229940046413 calcium iodide Drugs 0.000 claims description 2
- 229910001640 calcium iodide Inorganic materials 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 231100000053 low toxicity Toxicity 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 239000011575 calcium Substances 0.000 abstract description 16
- 230000035602 clotting Effects 0.000 abstract description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 15
- 206010053567 Coagulopathies Diseases 0.000 abstract description 15
- 229910052791 calcium Inorganic materials 0.000 abstract description 14
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 12
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 12
- 230000023597 hemostasis Effects 0.000 abstract description 7
- 230000015271 coagulation Effects 0.000 abstract description 3
- 238000005345 coagulation Methods 0.000 abstract description 3
- 238000005342 ion exchange Methods 0.000 abstract description 3
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 9
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 150000002500 ions Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present invention relates to blood clotting agents/medical devices and methods of controlling bleeding in animals and humans. More particularly, the present invention relates to the effectiveness of zeolites that have not been ion exchanged with calcium in promoting blood clotting provided that calcium ions are separately added along with the zeolites to the wound.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des zéolites à échange de calcium qui sont efficaces dans une hémostase. La raison pour laquelle des zéolites à échange de Ca sont nécessaires n'a pas été expliquée dans la technique antérieure, excepté que la présence d'ions Ca2+ est importante dans le mécanisme de coagulation. On sait maintenant que l'ajout d'ions Ca2+ ralentit réellement la coagulation du sang. L'utilisation de zéolites de Ca apparaît comme étant efficace dans une hémostase simplement du fait qu'elles ne suppriment pas le Ca2+ critique du sang par un échange d'ions. Une zéolite de NaA pourvue d'une quantité efficace de sel de Ca2+ ajouté est presque aussi active dans une coagulation que la forme à échange de Ca de zéolite de CaA.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07841971A EP2059187A2 (fr) | 2006-09-08 | 2007-09-06 | Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits |
| CN200780033033A CN101677848A (zh) | 2006-09-08 | 2007-09-06 | 具有加入的钙盐的非钙沸石在止血装置和产品中的用途 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53036906A | 2006-09-08 | 2006-09-08 | |
| US11/530,369 | 2006-09-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008030964A2 true WO2008030964A2 (fr) | 2008-03-13 |
| WO2008030964A3 WO2008030964A3 (fr) | 2008-05-08 |
Family
ID=39158050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/077763 WO2008030964A2 (fr) | 2006-09-08 | 2007-09-06 | Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2059187A2 (fr) |
| CN (1) | CN101677848A (fr) |
| WO (1) | WO2008030964A2 (fr) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008202A (en) * | 1988-11-29 | 1991-04-16 | Sequoia Turner Corporation | Blood diluent for red blood cell analysis |
| US5861146A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Method for reducing body odor |
| US5863581A (en) * | 1996-04-25 | 1999-01-26 | Lipton, Division Of Conopco, Inc. | Tea processing with zeolites |
| US6100414A (en) * | 1998-04-02 | 2000-08-08 | Eastman Chemical Company | Cyclopentadienyl transition metal compounds useful as polymerization catalysts |
| US6521265B1 (en) * | 2000-02-09 | 2003-02-18 | Biolife, L.L.C. | Method for applying a blood clotting agent |
| US20030133990A1 (en) * | 2000-10-13 | 2003-07-17 | Hursey Francis X. | Bandage using molecular sieves |
| US20040219208A1 (en) * | 2001-08-03 | 2004-11-04 | Ryu Kawamura | Sustained-release medicines |
| US20040258826A1 (en) * | 2001-12-20 | 2004-12-23 | Navarro Y Koren Peter Antonio | Matrix-forming composition containing pectin |
| US20050074505A1 (en) * | 2003-09-12 | 2005-04-07 | Hursey Francis X. | Calcium zeolite hemostatic agent |
| US20060178609A1 (en) * | 2005-02-09 | 2006-08-10 | Z-Medica, Llc | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
-
2007
- 2007-09-06 WO PCT/US2007/077763 patent/WO2008030964A2/fr active Application Filing
- 2007-09-06 EP EP07841971A patent/EP2059187A2/fr not_active Withdrawn
- 2007-09-06 CN CN200780033033A patent/CN101677848A/zh active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008202A (en) * | 1988-11-29 | 1991-04-16 | Sequoia Turner Corporation | Blood diluent for red blood cell analysis |
| US5863581A (en) * | 1996-04-25 | 1999-01-26 | Lipton, Division Of Conopco, Inc. | Tea processing with zeolites |
| US5861146A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Method for reducing body odor |
| US6100414A (en) * | 1998-04-02 | 2000-08-08 | Eastman Chemical Company | Cyclopentadienyl transition metal compounds useful as polymerization catalysts |
| US6521265B1 (en) * | 2000-02-09 | 2003-02-18 | Biolife, L.L.C. | Method for applying a blood clotting agent |
| US20030133990A1 (en) * | 2000-10-13 | 2003-07-17 | Hursey Francis X. | Bandage using molecular sieves |
| US20040219208A1 (en) * | 2001-08-03 | 2004-11-04 | Ryu Kawamura | Sustained-release medicines |
| US20040258826A1 (en) * | 2001-12-20 | 2004-12-23 | Navarro Y Koren Peter Antonio | Matrix-forming composition containing pectin |
| US20050074505A1 (en) * | 2003-09-12 | 2005-04-07 | Hursey Francis X. | Calcium zeolite hemostatic agent |
| US20060178609A1 (en) * | 2005-02-09 | 2006-08-10 | Z-Medica, Llc | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008030964A3 (fr) | 2008-05-08 |
| CN101677848A (zh) | 2010-03-24 |
| EP2059187A2 (fr) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1667623B1 (fr) | Agent hemostatique partiellement hydrate | |
| Pourshahrestani et al. | Well-ordered mesoporous silica and bioactive glasses: promise for improved hemostasis | |
| EP1983951B1 (fr) | Dispositifs hémostatiques contenant un adsorbant | |
| US20080145455A1 (en) | Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents | |
| US8883194B2 (en) | Adsorbent-containing hemostatic devices | |
| US20080254147A1 (en) | Method of providing hemostasis in anti-coagulated blood | |
| US20090047366A1 (en) | Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants | |
| EP1679087B1 (fr) | Matériaux contenant du tamis moléculaire ayant un diamètre de particules agrandi pour la formation de caillots sanguins | |
| WO2008128149A2 (fr) | Procédé d'hémostase dans du sang anti-coagulé | |
| US20050074505A1 (en) | Calcium zeolite hemostatic agent | |
| US20020141964A1 (en) | Composition for arresting the flow of blood and method | |
| US20080063697A1 (en) | Use of Unactivated Calcium Exchanged Zeolites in Hemostatic Devices and Products | |
| EP2059187A2 (fr) | Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits | |
| US20080145447A1 (en) | Inorganic Solids That Accelerate Coagulation of Blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200780033033.4 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07841971 Country of ref document: EP Kind code of ref document: A2 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007841971 Country of ref document: EP |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2228/DELNP/2009 Country of ref document: IN |